Response to 'Neither earlier not late tocilizumab improved outcomes in the intensive care unit patients with COVID-19 in a retrospective cohort study' by Moiseev et al

We read with interest the letter from Moiseev et al 1 on our COVID High-intensity Immunosuppression in Cytokine storm syndrome study.2 In our study, we have used an immunosuppressive strategy composed by glucocorticoids in the first line, followed, in case of insufficient response, by tocilizumab in patients with COVID-19-associated cytokine storm syndrome (CSS). Moiseev et al share with us the results of their study in which they have treated patients with COVID-19 with tocilizumab. In a retrospective study, the authors compared the outcomes of patients treated with tocilizumab with those of patients not treated with it. Patients could receive tocilizumab in the presence of bilateral pneumonia involving at least 50% of lung tissue and requiring …